These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice. Kerrick WG; Kazmierczak K; Xu Y; Wang Y; Szczesna-Cordary D FASEB J; 2009 Mar; 23(3):855-65. PubMed ID: 18987303 [TBL] [Abstract][Full Text] [Related]
9. Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. Abraham TP; Jones M; Kazmierczak K; Liang HY; Pinheiro AC; Wagg CS; Lopaschuk GD; Szczesna-Cordary D Cardiovasc Res; 2009 Apr; 82(1):84-92. PubMed ID: 19150977 [TBL] [Abstract][Full Text] [Related]
10. The effect of myosin RLC phosphorylation in normal and cardiomyopathic mouse hearts. Muthu P; Kazmierczak K; Jones M; Szczesna-Cordary D J Cell Mol Med; 2012 Apr; 16(4):911-9. PubMed ID: 21696541 [TBL] [Abstract][Full Text] [Related]
11. Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions. Duggal D; Nagwekar J; Rich R; Huang W; Midde K; Fudala R; Das H; Gryczynski I; Szczesna-Cordary D; Borejdo J Am J Physiol Heart Circ Physiol; 2015 May; 308(10):H1248-57. PubMed ID: 25770245 [TBL] [Abstract][Full Text] [Related]
12. Molecular basis of force-pCa relation in Yuan CC; Kazmierczak K; Liang J; Ma W; Irving TC; Szczesna-Cordary D Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35177471 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM. Yadav S; Yuan CC; Kazmierczak K; Liang J; Huang W; Takeuchi LM; Kanashiro-Takeuchi RM; Szczesna-Cordary D J Mol Med (Berl); 2019 Jul; 97(7):1033-1047. PubMed ID: 31101927 [TBL] [Abstract][Full Text] [Related]
14. Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice. Kazmierczak K; Muthu P; Huang W; Jones M; Wang Y; Szczesna-Cordary D Biochem J; 2012 Feb; 442(1):95-103. PubMed ID: 22091967 [TBL] [Abstract][Full Text] [Related]
15. Familial hypertrophic cardiomyopathy can be characterized by a specific pattern of orientation fluctuations of actin molecules . Borejdo J; Szczesna-Cordary D; Muthu P; Calander N Biochemistry; 2010 Jun; 49(25):5269-77. PubMed ID: 20509708 [TBL] [Abstract][Full Text] [Related]
16. Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy. Kazmierczak K; Paulino EC; Huang W; Muthu P; Liang J; Yuan CC; Rojas AI; Hare JM; Szczesna-Cordary D Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H575-89. PubMed ID: 23748425 [TBL] [Abstract][Full Text] [Related]
17. Mechanistic basis for rescuing hypertrophic cardiomyopathy with myosin regulatory light chain phosphorylation. Liang J; Kazmierczak K; Veerasammy M; Yadav S; Takeuchi L; Kanashiro-Takeuchi R; Szczesna-Cordary D Cytoskeleton (Hoboken); 2024 Dec; 81(12):806-814. PubMed ID: 38494592 [TBL] [Abstract][Full Text] [Related]
18. The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice. Szczesna-Cordary D; Guzman G; Zhao J; Hernandez O; Wei J; Diaz-Perez Z J Cell Sci; 2005 Aug; 118(Pt 16):3675-83. PubMed ID: 16076902 [TBL] [Abstract][Full Text] [Related]
19. Mavacamten decreases maximal force and Ca Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957 [TBL] [Abstract][Full Text] [Related]
20. Impact of familial hypertrophic cardiomyopathy-linked mutations in the NH2 terminus of the RLC on β-myosin cross-bridge mechanics. Farman GP; Muthu P; Kazmierczak K; Szczesna-Cordary D; Moore JR J Appl Physiol (1985); 2014 Dec; 117(12):1471-7. PubMed ID: 25324513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]